Evaluation of a Peer Recovery Support Program Adapted to Target Retention in Clinic-based Medication for Opioid Use Disorder Treatment

Not Applicable

Not yet recruiting

• Conditions: Opioid Use Disorder

• Registration Number: NCT07197801
• Lead Sponsor: Geisinger Clinic

Brief Summary

The goal of this clinical trial is to learn if receiving peer recovery support (support services provided by trained "peers" with lived experience of addiction and recovery) improves retention in medication treatment among people with opioid use disorder. The main question it aims to answer is: does peer recovery support improve retention in medication treatment for opioid use disorder?

Researchers will compare two groups: (1) standard care combined with a peer recovery support program, and (2) standard care alone, to see if peer recovery support works to improve retention in medication treatment for opioid use disorder.

Participants will: visit clinics as they normally would to receive standard care (medication treatment for opioid use disorder); complete two questionnaires - one when they start treatment and one 6 months later; and agree to let researchers use information from their medical record. Participants in group 1 will also be invited to meet with a peer recovery support specialist for up to 6 months.

Detailed Description

Not available

Study Timeline

• Status Verified: 2025-09
• Study First Submitted: 2025-09-26
• Study First Submitted QC: 2025-09-26
• Last Update Submitted: 2025-09-26
• Study First Posted: 2025-09-29
• Last Update Posted: 2025-09-29
• Study Start: 2026-01-02
• Primary Completion: 2029-01-31
• Study Completion: 2029-07-31

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 218

Inclusion Criteria

• Adult ≥ 18 years of age
• Initiated medication for opioid use disorder treatment in past 45 days in a Geisinger outpatient clinic
• Willing and able to give informed consent

Exclusion Criteria

• Received medication for opioid use disorder treatment at a Geisinger outpatient clinic in the 90-day period prior to the treatment initiation date
• Not proficient in English

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
6-month treatment retention	180 days from initiation of medication treatment for opioid use disorder	Data will come from the electronic health records. Retention will be defined as a participant: 1) having a current order for a medication for opioid use disorder treatment (buprenorphine, buprenorphine-naloxone, or naltrexone) at the 6-month follow-up date (based on the days' supply); and 2) not having a lapse in days' supply of medication within the 6-month follow-up period that is greater than 30 days.
Length of time in treatment	180 days from initiation of medication treatment for opioid use disorder	Data will come from the electronic health records. Length of time in treatment will be determined by summing days' supply of consecutive orders for medications for opioid use disorder treatment(buprenorphine, buprenorphine- naloxone, or naltrexone). Treatment will be considered ended if a participant has a gap in supply of more than 30 days.

Trial Locations

Locations (1)

Geisinger Clinic; 🇺🇸 Danville, Pennsylvania, United States